Get the Stockscreener App
22.87
0.44%
0.07
Pacira Biosciences Inc stock is traded at $22.87, with a volume of 123.17K.
It is up +0.44% in the last 24 hours and up +4.00% over the past month.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
See More
Previous Close:
$22.80
Open:
$22.76
24h Volume:
123.17K
Relative Volume:
0.20
Market Cap:
$984.76M
Revenue:
$681.75M
Net Income/Loss:
$70.47M
P/E Ratio:
15.77
EPS:
1.45
Net Cash Flow:
$173.19M
1W Performance:
-3.70%
1M Performance:
+4.00%
6M Performance:
-12.39%
1Y Performance:
+31.76%
1-Day Range:
$22.29
$22.93
1-Week Range:
$22.29
$24.95
52-Week Range:
$16.29
$27.98
Pacira Biosciences Inc Stock (PCRX) Company Profile
Name
Pacira Biosciences Inc
Sector
Phone
650-242-8052
Address
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
22.89 | 980.89M | 681.75M | 70.47M | 173.19M | 1.45 |
|
ZTS
Zoetis Inc
|
118.31 | 51.07B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.29 | 44.42B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.915 | 42.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.11 | 27.86B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.46 | 20.44B | 3.08B | 1.24B | 1.07B | 25.61 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-25 | Initiated | H.C. Wainwright | Buy |
| Jul-25-25 | Upgrade | Truist | Hold → Buy |
| Jan-30-25 | Upgrade | Truist | Sell → Hold |
| Aug-13-24 | Downgrade | Truist | Buy → Sell |
| Aug-12-24 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-12-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-12-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-03-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-07-24 | Resumed | JP Morgan | Overweight |
| Dec-20-23 | Initiated | Raymond James | Outperform |
| Aug-03-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jan-31-23 | Resumed | Wedbush | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Jan-03-22 | Resumed | JP Morgan | Overweight |
| Jul-26-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-21-21 | Resumed | JP Morgan | Neutral |
| Apr-09-21 | Initiated | Berenberg | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-11-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jan-21-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-06-20 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Apr-07-20 | Initiated | Northland Capital | Outperform |
| Mar-20-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-24-20 | Initiated | SunTrust | Buy |
| Jan-23-20 | Initiated | SunTrust | Buy |
| Nov-06-19 | Initiated | BTIG Research | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-06-19 | Upgrade | Mizuho | Underperform → Neutral |
| May-02-19 | Upgrade | Stifel | Sell → Hold |
| Feb-01-19 | Downgrade | Mizuho | Neutral → Underperform |
| Aug-06-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Apr-09-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-21-18 | Reiterated | Mizuho | Neutral |
| Feb-16-18 | Downgrade | Needham | Buy → Hold |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Jan-04-18 | Reiterated | Canaccord Genuity | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Mkt Perform |
View All
Pacira Biosciences Inc Stock (PCRX) Latest News
What macro factors could drive Pacira BioSciences Inc. (82P) stock higherJuly 2025 Highlights & Safe Swing Trade Setup Alerts - newser.com
Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Is Pacira BioSciences Inc. (82P) stock attractive for dividend growth2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Is Pacira BioSciences Inc. (82P) stock a top pick for value investorsMarket Sentiment Report & Weekly Sector Rotation Insights - newser.com
Will Pacira BioSciences Inc. stock rally after Fed decisionsJuly 2025 Retail & AI Forecasted Entry and Exit Points - newser.com
How Pacira BioSciences Inc. (82P) stock moves in volatile trading sessions2025 Short Interest & Fast Gaining Stock Reports - newser.com
Will Pacira BioSciences Inc. (82P) stock beat Nasdaq index returnsWeekly Trend Report & Daily Chart Pattern Signals - newser.com
How Pacira BioSciences Inc. stock valuations compare to rivalsTrade Exit Report & Advanced Swing Trade Entry Plans - newser.com
What is the fair value estimate for Pacira BioSciences Inc. (82P) stock in 2025Weekly Trade Analysis & Technical Buy Zone Confirmations - newser.com
Why Pacira BioSciences Inc. (82P) stock attracts wealthy investorsEarnings Growth Summary & Fast Gain Stock Trading Tips - newser.com
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Insider Sell: Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX) - GuruFocus
Real time social sentiment graph for Pacira BioSciences Inc.Weekly Trade Summary & Community Consensus Picks - newser.com
Will Pacira BioSciences Inc. (82P) stock deliver compounding returnsBull Run & Weekly Top Gainers Trade List - newser.com
Should I hold or sell Pacira BioSciences Inc. stock in 20252025 Performance Recap & Real-Time Buy Signal Notifications - newser.com
How Pacira BioSciences Inc. (82P) stock valuation compares with sector2025 Volume Leaders & AI Forecasted Entry and Exit Points - newser.com
Is Pacira BioSciences Inc. stock poised for growthTrade Volume Summary & Entry Point Confirmation Signals - newser.com
Will Pacira BioSciences Inc. stock keep outperforming rivalsWeekly Market Summary & Real-Time Buy Signal Alerts - newser.com
Will Pacira BioSciences Inc. (82P) stock benefit from mergers2025 Sector Review & Daily Chart Pattern Signal Reports - newser.com
Using data tools to time your Pacira BioSciences Inc. exitJuly 2025 Chart Watch & Daily Market Momentum Tracking - newser.com
(PCRX) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
How to use a screener to detect Pacira BioSciences Inc. breakoutsFed Meeting & Safe Capital Investment Plans - newser.com
What analysts say about Pacira BioSciences Inc 82P stockPrice-to-Book Ratio Updates & Free Real-Time Trading Signals - earlytimes.in
Pacira Biosciences Inc Stock (PCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
2.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):